Pharmaceutical News

RSS

FDA approves two drugs for long-term weight loss

Options are limited in America's battle of the bulge. While diet and exercise can help in the short term, they are frustratingly ineffective in the long run.

12 Feb 2014

IMF announces approval of POMALYST medication in Canada for patients with myeloma

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - said POMALYST (pomalidomide) approval by Health Canada provides patients the most up-to-date oral therapy available for patients who have exhausted all other treatments.

11 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Tamoxifen drug appears to kill fungus associated with deadly brain infection

The drug tamoxifen appears to kill a fungus associated with a deadly brain infection that afflicts HIV/AIDS patients, according to a University of Rochester study published online today by mBio, the journal of the American Society for Microbiology.

11 Feb 2014

Cardiome Pharma's subsidiary signs agreement with Tamro to distribute BRINAVESS in Sweden

Cardiome Pharma Corp. today announced that its subsidiary, Correvio GmbH, has entered into an agreement with Tamro AB, headquartered in Gothenburg, Sweden, to distribute BRINAVESS (vernakalant IV) to customers in the Swedish market.

11 Feb 2014

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.

11 Feb 2014

Drug used for treating breast cancer also kills fungal disease

Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more HIV/AIDS patients than tuberculosis, appear in mBio-, the online open-access journal of the American Society for Microbiology (ASM.)

11 Feb 2014

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.

10 Feb 2014

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme.

10 Feb 2014

Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes

Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.

10 Feb 2014

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees.

10 Feb 2014

New study analyses risk factors and mortality among heroin, cocaine consumers admitted to treatment

A new study analyses the risk factors and excess mortality among heroin and cocaine consumers admitted to treatment in Spain. The results reveal that the fatality rate among consumers of both drugs is 14.3 times higher than for the general population, while among those only using cocaine, it is 5.1 times higher.

10 Feb 2014

New method to build tiny degradable 'medicine factories' inside the body

A factory built of gel does not sound very durable. But the new type of micro-factories invented by researchers at Aarhus University do not have to last.

9 Feb 2014

Finding could lead to first effective vaccine against respiratory syncytial virus

Vanderbilt University scientists have contributed to a major finding, reported today in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.

9 Feb 2014

Loyola University toxicologist to talk about rise seen in heroin overdoses in recent years

In the wake of actor Philip Seymour Hoffman's death, Loyola University Health System toxicologist Christina Hantsch, MD, FACEP, FACMT, is available to talk about the rise she has seen in heroin overdoses in recent years.

7 Feb 2014

Study: Investigational drug effective in reducing mucormycosis infections

With very few treatment options available to fight deadly mucormycosis infections, a new Los Angeles Biomedical Research Institute (LA BioMed) study holds hope for adding to the arsenal of therapies physicians have to combat an increasingly common infection afflicting people with weakened immune systems.

7 Feb 2014

Combination of etoposide with compounds that interfere with cell division improves therapeutic window for cancer treatments

A large part of the effort dedicated to cancer research is directed towards the search for combinations of existing drugs-many of which have already been introduced into clinical practice-that permit higher overall survival rates and improvements in the quality of life of cancer patients.

7 Feb 2014

Children with FSE who receive earlier treatment with AEDs experience reduction in duration of seizure

New research shows that children with febrile status epilepticus (FSE) who receive earlier treatment with antiepileptic drugs (AEDs) experience a reduction in the duration of the seizure.

6 Feb 2014

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality.

6 Feb 2014

Researchers design new vaccine for human-infecting respiratory syncytial virus

Vaccines are the safest, cheapest and most effective way to protect against infectious diseases. But to make a good one is still a challenge, and traditional approaches are now stretched to the limit while fatal diseases, like HIV and malaria, remain without vaccine.

6 Feb 2014

Pharmaceutical News

FDA approves two drugs for long-term weight loss

IMF announces approval of POMALYST medication in Canada for patients with myeloma

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Tamoxifen drug appears to kill fungus associated with deadly brain infection

Cardiome Pharma's subsidiary signs agreement with Tamro to distribute BRINAVESS in Sweden

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Drug used for treating breast cancer also kills fungal disease

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes

Mallinckrodt announces commercial launch of PENNSAID

New study analyses risk factors and mortality among heroin, cocaine consumers admitted to treatment

New method to build tiny degradable 'medicine factories' inside the body

Finding could lead to first effective vaccine against respiratory syncytial virus

Loyola University toxicologist to talk about rise seen in heroin overdoses in recent years

Study: Investigational drug effective in reducing mucormycosis infections

Combination of etoposide with compounds that interfere with cell division improves therapeutic window for cancer treatments

Children with FSE who receive earlier treatment with AEDs experience reduction in duration of seizure

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Researchers design new vaccine for human-infecting respiratory syncytial virus

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News